Iowa lawmakers introduce bills to stop Pharmacy Benefit Managers from giving pharmacies less money than it costs to fill prescriptions.

Bristol-Myers Squibb (NYSE:BMY), a global biopharmaceutical company with a market capitalization of nearly $120 billion, finds itself at a critical juncture as it navigates a complex landscape of ...

Financial analysis of Pfizer Inc. stock ahead of its earnings release. PFE faces significant headwinds from patent expiries, click for my updated look at the stock.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ...

President Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals.

Donald Trump is executing a shock and awe strategy, burying the public in a smoky cloud of flamboyant proposals. Some, like ending birthright citizenship, ...

The Centers for Medicare and Medicaid Services (CMS) says about 8,247,000 people with Medicare Part D coverage use the ten drugs selected for price negotiation.

You'll get access to an ad-free website with a faster photo browser, the chance to claim free tickets to a host of events ...

The company also pointed out that the MFP "is the price Medicare will pay for Eliquis and does not set what Medicare patients will pay for the drug now or in the future. Insurance plans and their ...

We recently compiled a list of the 12 Best Blue Chip Stocks to Buy Under $100. In this article, we are going to take a look at where Bristol-Myers Squibb Company (NYSE:BMY) stands against other best ...

Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action.

President Donald Trump is executing a "shock and awe" strategy, burying the public in a smoky cloud of flamboyant proposals.